Entinostat

Entinostat

Entinostat

Entinostat, also known by its trade name SNDX-275, is a histone deacetylase inhibitor (HDAC inhibitor) that is used in cancer treatment. It is a synthetic benzamide derivative that has been shown to have antineoplastic activity.

Mechanism of Action

Entinostat inhibits the activity of histone deacetylase, an enzyme that is involved in the regulation of gene expression. By inhibiting this enzyme, entinostat can alter the expression of genes that are involved in cell growth and differentiation, leading to the death of cancer cells.

Clinical Use

Entinostat is used in the treatment of various types of cancer, including breast cancer, lung cancer, and leukemia. It is often used in combination with other chemotherapy drugs to enhance their effectiveness.

Side Effects

Common side effects of entinostat include fatigue, nausea, and vomiting. More serious side effects can include anemia, neutropenia, and thrombocytopenia.

Research

Research is ongoing to determine the full range of cancers that can be treated with entinostat, as well as to better understand its mechanism of action. Clinical trials are also being conducted to evaluate the safety and effectiveness of entinostat in combination with other drugs.

See Also

• Histone deacetylase inhibitor
• Cancer treatment
• Chemotherapy

‎

‎